Luke Sergott
Stock Analyst at Barclays
(2.37)
# 2,512
Out of 5,163 analysts
389
Total ratings
40.83%
Success rate
-0.19%
Average return
Main Sectors:
Stocks Rated by Luke Sergott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ICLR ICON Public Limited Company | Maintains: Equal-Weight | $200 → $120 | $98.33 | +22.04% | 24 | Mar 9, 2026 | |
| MEDP Medpace Holdings | Upgrades: Equal-Weight | $500 | $450.41 | +11.01% | 7 | Mar 6, 2026 | |
| PACB Pacific Biosciences of California | Downgrades: Underweight | $2 → $1.5 | $1.33 | +12.78% | 7 | Mar 6, 2026 | |
| IQV IQVIA Holdings | Upgrades: Overweight | $210 | $164.72 | +27.49% | 26 | Mar 6, 2026 | |
| CERT Certara | Downgrades: Equal-Weight | $8 | $6.65 | +20.30% | 22 | Mar 6, 2026 | |
| AVTR Avantor | Downgrades: Underweight | $8.5 | $7.93 | +7.19% | 29 | Mar 6, 2026 | |
| FTRE Fortrea Holdings | Maintains: Equal-Weight | $15 → $12 | $8.94 | +34.23% | 15 | Feb 27, 2026 | |
| A Agilent Technologies | Maintains: Overweight | $165 → $150 | $111.51 | +34.52% | 15 | Feb 26, 2026 | |
| RGEN Repligen | Maintains: Overweight | $200 → $175 | $114.20 | +53.24% | 5 | Feb 25, 2026 | |
| CRL Charles River Laboratories International | Maintains: Overweight | $215 → $200 | $155.46 | +28.65% | 12 | Feb 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $325 → $265 | $235.46 | +12.55% | 5 | Feb 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $50 | $33.75 | +48.15% | 9 | Feb 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Overweight | $400 | $286.57 | +39.58% | 19 | Feb 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $50 | $43.28 | +15.53% | 21 | Feb 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $115 → $118 | $85.57 | +37.90% | 13 | Feb 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $625 → $650 | $464.37 | +39.97% | 30 | Jan 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $52 | $40.60 | +29.01% | 3 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $230 → $270 | $187.85 | +43.73% | 6 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $1,600 → $1,550 | $1,173.74 | +32.06% | 4 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $100 → $110 | $118.94 | -7.52% | 22 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $85 → $120 | $85.49 | +40.37% | 6 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $22 | $18.79 | +17.08% | 15 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $77 → $105 | $103.57 | +1.38% | 9 | Nov 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $19 → $20 | $13.42 | +49.09% | 23 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $225 → $250 | $187.32 | +33.46% | 41 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $92.54 | -2.74% | 1 | Aug 1, 2025 |
ICON Public Limited Company
Mar 9, 2026
Maintains: Equal-Weight
Price Target: $200 → $120
Current: $98.33
Upside: +22.04%
Medpace Holdings
Mar 6, 2026
Upgrades: Equal-Weight
Price Target: $500
Current: $450.41
Upside: +11.01%
Pacific Biosciences of California
Mar 6, 2026
Downgrades: Underweight
Price Target: $2 → $1.5
Current: $1.33
Upside: +12.78%
IQVIA Holdings
Mar 6, 2026
Upgrades: Overweight
Price Target: $210
Current: $164.72
Upside: +27.49%
Certara
Mar 6, 2026
Downgrades: Equal-Weight
Price Target: $8
Current: $6.65
Upside: +20.30%
Avantor
Mar 6, 2026
Downgrades: Underweight
Price Target: $8.5
Current: $7.93
Upside: +7.19%
Fortrea Holdings
Feb 27, 2026
Maintains: Equal-Weight
Price Target: $15 → $12
Current: $8.94
Upside: +34.23%
Agilent Technologies
Feb 26, 2026
Maintains: Overweight
Price Target: $165 → $150
Current: $111.51
Upside: +34.52%
Repligen
Feb 25, 2026
Maintains: Overweight
Price Target: $200 → $175
Current: $114.20
Upside: +53.24%
Charles River Laboratories International
Feb 19, 2026
Maintains: Overweight
Price Target: $215 → $200
Current: $155.46
Upside: +28.65%
Feb 13, 2026
Maintains: Equal-Weight
Price Target: $325 → $265
Current: $235.46
Upside: +12.55%
Feb 13, 2026
Maintains: Overweight
Price Target: $55 → $50
Current: $33.75
Upside: +48.15%
Feb 11, 2026
Reinstates: Overweight
Price Target: $400
Current: $286.57
Upside: +39.58%
Feb 3, 2026
Maintains: Overweight
Price Target: $39 → $50
Current: $43.28
Upside: +15.53%
Feb 3, 2026
Maintains: Overweight
Price Target: $115 → $118
Current: $85.57
Upside: +37.90%
Jan 30, 2026
Maintains: Overweight
Price Target: $625 → $650
Current: $464.37
Upside: +39.97%
Dec 15, 2025
Maintains: Overweight
Price Target: $50 → $52
Current: $40.60
Upside: +29.01%
Dec 15, 2025
Maintains: Overweight
Price Target: $230 → $270
Current: $187.85
Upside: +43.73%
Dec 15, 2025
Maintains: Overweight
Price Target: $1,600 → $1,550
Current: $1,173.74
Upside: +32.06%
Dec 15, 2025
Maintains: Underweight
Price Target: $100 → $110
Current: $118.94
Upside: -7.52%
Dec 15, 2025
Maintains: Overweight
Price Target: $85 → $120
Current: $85.49
Upside: +40.37%
Dec 15, 2025
Maintains: Overweight
Price Target: $17 → $22
Current: $18.79
Upside: +17.08%
Nov 21, 2025
Downgrades: Equal-Weight
Price Target: $77 → $105
Current: $103.57
Upside: +1.38%
Nov 5, 2025
Maintains: Overweight
Price Target: $19 → $20
Current: $13.42
Upside: +49.09%
Oct 22, 2025
Maintains: Overweight
Price Target: $225 → $250
Current: $187.32
Upside: +33.46%
Aug 1, 2025
Initiates: Overweight
Price Target: $90
Current: $92.54
Upside: -2.74%